Director - Diagnostics Partnering

Caris Life Sciences

8d•Hybrid

About The Position

At Caris, we understand that cancer is an ugly word—a word no one wants to hear, but one that connects us all. That’s why we’re not just transforming cancer care—we’re changing lives. We introduced precision medicine to the world and built an industry around the idea that every patient deserves answers as unique as their DNA. Backed by cutting-edge molecular science and AI, we ask ourselves every day: “What would I do if this patient were my mom?” That question drives everything we do. But our mission doesn’t stop with cancer. We're pushing the frontiers of medicine and leading a revolution in healthcare—driven by innovation, compassion, and purpose. Join us in our mission to improve the human condition across multiple diseases. If you're passionate about meaningful work and want to be part of something bigger than yourself, Caris is where your impact begins. Position Summary We are seeking a strategic and collaborative Diagnostic (Dx) Lead to spearhead our biopharma partnerships and drive the co-development and lead opportunities for NGS and IHC-based profiling and companion diagnostics opportunities in oncology. This role is central to shaping and executing partnership strategies that leverage our diagnostic platform with the biomarker and therapeutic needs of leading biopharmaceutical companies. The ideal candidate brings a deep understanding of the precision oncology landscape, a strong commercial mindset, and the ability to build and manage cross-functional initiatives that deliver value to partners and patients.

Requirements

MS or PhD in molecular biology, genomics, oncology, or related field.
A minimum of 8 years professional work experience.
5+ years of experience in the molecular diagnostics, biopharma, or precision medicine sectors, with a clear focus on diagnostics and oncology.
Business Development.
Proven business development track record (e.g., deal sheet) leading diligences, and complex organization-wide efforts to deliver partnerships with Biopharma.
Transactions knowledge (e.g., contracting, deal sheets, multi-tier / multi-constituent decision making, etc.).
Experience as the external face of the organization, leading and participating in BD partnering events (e.g., JPM, BIO) and oncology conferences.
Lead customer demos and presentations both in-person and virtually.
Proven experience managing or supporting biopharma partnerships involving NGS or biomarker-driven programs.
Strong grasp of oncology therapeutic development, biomarker strategy, and regulatory pathways for Dx in global markets.
Excellent communication, negotiation, and program leadership skills.

Nice To Haves

MBA or equivalent commercial experience strongly preferred.
Business development or alliance management experience preferred.
Deep understanding of NGS technologies (panel-based, whole exome/genome, RNAseq) and their clinical application in oncology.
Experience with both LDT and IVD business models in a partner-driven context.
Familiarity with clinical trial design, biomarker assay development, and the evolving landscape of personalized medicine.

Responsibilities

Identify and pursue strategic opportunities for IHC and NGS based diagnostic programs for targeted therapies and immuno-oncology agents.
Serve as the strategic thought partner to senior executives and R D leadership at biopharma companies, fostering trust, strategic, and scientific alignment.
Serve as the BD lead managing diagnostic partnerships from early-stage evaluation through deal closing.
Define partnership value propositions by integrating our scientific strengths with the commercial needs of biopharma customers.
Oversee implementation of joint go-to-market plans, ensuring alignment on launch timing, geographies, messaging, and field deployment.
Help strengthen external materials that clearly communicate the value of our diagnostic offerings to clinicians, KOLs, and payers.
Lead diagnostic partnerships and act as a key escalation point, ensuring consistent communication between internal stakeholders and partner organizations.